Abstract | OBJECTIVES: METHODS: Eighty-seven rats with moderate myocardial infarction were randomized to receive either no drug or canrenone, the active metabolite of spironolactone, 20 mg/kg/day, or ramipril, 1 mg/kg/day, or a combination of the two drugs. Treatment was initiated 1 month after coronary ligation and lasted 4 weeks. Echocardiography was performed at baseline and after 4 weeks. LV catheterization, isolated heart studies, morphometric histology, myocardial norepinephrine and SERCA-2 mRNA were assessed at the end of the treatment period. RESULTS:
Infarct sizes were 33+/-3, 32+/-3, 34+/-3, and 34+/-4% in the placebo, canrenone, ramipril, and combination groups, respectively. Canrenone attenuated LV remodeling, improved LV systolic and diastolic function, and markedly reduced interstitial and perivascular fibrosis. These effects were increased by concomitant ramipril therapy. Moreover, myocardial norepinephrine content was decreased while ventricular fibrillation threshold significantly augmented by canrenone. SERCA-2 levels remained unchanged. CONCLUSIONS:
|
Authors | Antonio Cittadini, Maria Gaia Monti, Jörgen Isgaard, Cosma Casaburi, Hinrik Strömer, Angela Di Gianni, Raffaella Serpico, Lavinia Saldamarco, Massimo Vanasia, Luigi Saccà |
Journal | Cardiovascular research
(Cardiovasc Res)
Vol. 58
Issue 3
Pg. 555-64
(Jun 01 2003)
ISSN: 0008-6363 [Print] England |
PMID | 12798428
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Mineralocorticoid Receptor Antagonists
- RNA, Messenger
- Canrenone
- Sarcoplasmic Reticulum Calcium-Transporting ATPases
- Calcium-Transporting ATPases
- Ramipril
- Norepinephrine
|
Topics |
- Animals
- Calcium-Transporting ATPases
(genetics)
- Canrenone
(therapeutic use)
- Drug Therapy, Combination
- Heart Failure
(drug therapy, etiology, metabolism)
- Male
- Mineralocorticoid Receptor Antagonists
- Myocardial Infarction
(complications, drug therapy, metabolism)
- Myocardium
(metabolism)
- Norepinephrine
(genetics)
- RNA, Messenger
(analysis)
- Ramipril
(therapeutic use)
- Random Allocation
- Rats
- Rats, Sprague-Dawley
- Sarcoplasmic Reticulum Calcium-Transporting ATPases
- Ventricular Dysfunction, Left
(drug therapy)
- Ventricular Remodeling
(drug effects)
|